Taysha Gene Therapies, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
TSHA Nasdaq 2836 www.tayshagtx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Taysha Gene Therapies, Inc.

Taysha Gene Therapies Inc. (TSHA): A Promising Biotech on Rett Syndrome Drug Prospects - Jan 14th, 2026 12:13 pm
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - Jan 6th, 2026 6:00 am
Does Taysha Gene Therapies Still Offer Value After a 196.8% Year to Date Surge? - Dec 22nd, 2025 11:06 am
Is FDA Breakthrough Status For TSHA-102 Reshaping The Investment Case For Taysha Gene Therapies (TSHA)? - Dec 22nd, 2025 7:09 am
Taysha Gene Therapies (TSHA): Revisiting Valuation After Breakthrough Rett Data and Bullish Analyst Upgrades - Dec 22nd, 2025 6:06 am
Taysha Gene (TSHA) Hovers Around Its 52-Week High As It Continues to Advance Rett Syndrome Program - Dec 21st, 2025 5:31 am
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 5th, 2025 2:05 pm
Is Taysha Gene Therapies Inc. (TSHA) One of the Must-Buy Penny Stocks to Buy Now? - Nov 18th, 2025 4:17 am
Citizens Lifts Price Target for Taysha Gene Therapies (TSHA) - Nov 7th, 2025 7:34 pm
Taysha Gene Therapies (TSHA): Revenue Forecast to Grow 70.49% Annually, Unprofitability Drives Debate - Nov 4th, 2025 5:30 pm
Taysha Gene Therapies Inc (TSHA) Q3 2025 Earnings Call Highlights: Strategic Advances and ... - Nov 4th, 2025 2:09 pm
Taysha Gene Therapies (TSHA): Assessing Valuation Following Strong Share Price Gains - Nov 4th, 2025 11:11 am
Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Nov 4th, 2025 5:00 am
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - Oct 28th, 2025 6:00 am
Taysha Gene Therapies Regains Full Global Rights to Lead Rett Syndrome Program TSHA-102 - Oct 26th, 2025 4:43 am
Raymond James Initiates Strong Buy on Taysha (TSHA) Amid Rett Syndrome Trial Momentum - Oct 26th, 2025 4:16 am
How Regaining Full Rights to Rett Syndrome Gene Therapy Has Changed Taysha (TSHA)’s Investment Story - Oct 17th, 2025 6:18 pm
I-Mab morphs into ‘hub-and-spoke’ biotech; Astellas passes on Taysha gene therapy - Oct 17th, 2025 4:00 am
Personalis (PSNL) Moves 20.5% Higher: Will This Strength Last? - Oct 17th, 2025 1:14 am
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome - Oct 16th, 2025 2:01 pm